<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT02191228</url>
  </required_header>
  <id_info>
    <org_study_id>1218.26</org_study_id>
    <nct_id>NCT02191228</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Single and Multiple Doses of Linagliptin Tablets in Patients With Different Degrees of Renal Impairment in Comparison to Subjects With Normal Renal Function</brief_title>
  <official_title>Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Single and Multiple 5 mg Doses of Linagliptin Tablets in Patients With Different Degrees of Renal Impairment in Comparison to Subjects With Normal Renal Function in a Monocentric, Open, Parallel-group, Phase I Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The main objective of this study was to assess the effect of normal and impaired renal&#xD;
      function on the safety, pharmacokinetics, and pharmacodynamics of linagliptin following oral&#xD;
      administration of 5 mg daily for 7 days (Groups 1 to 3), 5 mg daily for 10 days (Groups 6 and&#xD;
      7), or as a single dose (Groups 4 and 5)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUCτ,ss (area under the concentration time curve of the analyte in plasma over the time interval from 0 to 24h after the last dose at steady state) - multiple dose groups</measure>
    <time_frame>up to 480 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax,ss (maximum concentration of the analyte in plasma at steady state) - multiple dose groups</measure>
    <time_frame>up to 480 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-24 (area under the concentration time curve of the analyte in plasma over the time interval from 0 to 24h after the first dose) - single dose groups</measure>
    <time_frame>up to 24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax (maximum concentration of the analyte in plasma) - single dose groups</measure>
    <time_frame>up to 264 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>tmax,(ss) (time from last dosing to maximum concentration of the analyte in plasma after the first dose or at steady state) - multiple dose groups</measure>
    <time_frame>up to 480 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C24,(ss) (concentration of the analyte in plasma at steady state after administration of the first or last dose at the end of the dosing interval) - multiple dose groups</measure>
    <time_frame>up to 480 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>λz,(ss) (terminal rate constant in plasma after single dose/at steady state) - multiple dose groups</measure>
    <time_frame>up to 480 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>t1/2,(ss) (terminal half-life of the analyte in plasma after single dose/at steady state) - multiple dose groups</measure>
    <time_frame>up to 480 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRTpo,(ss) (mean residence time of the analyte in the body after single dose/at steady state after oral administration) - multiple dose groups</measure>
    <time_frame>up to 480 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CL/F,(ss) (apparent clearance of the analyte in the plasma after extravascular administration after single dose/at steady state) - multiple dose groups</measure>
    <time_frame>up to 480 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vz/F,(ss) (apparent volume of distribution during the terminal phase λz after single dose/at steady state following extravascular administration) - multiple dose groups</measure>
    <time_frame>up to 480 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-∞ (area under the concentration time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity after single dose in severely impaired or end stage renal disease (ESRD) patients)</measure>
    <time_frame>up to 264 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point after single dose in severely impaired or ESRD patients)</measure>
    <time_frame>up to 264 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>%AUCtz-∞ (percentage of area under the concentration-time curve of the analyte in plasma over the time interval from the time of the last quantifiable data point extrapolated to infinity after single dose in severely impaired or ESRD patients)</measure>
    <time_frame>up to 264 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of Plasma protein binding</measure>
    <time_frame>predose Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Model-derived AUCτ,ss in severely impaired or ESRD patients</measure>
    <time_frame>up to 264 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Model-derived Cmax,ss in severely impaired or ESRD patients</measure>
    <time_frame>up to 264 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Dipeptidyl peptidase IV (DPP-4) activity in plasma</measure>
    <time_frame>up to 480 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with abnormal findings in physical examination</measure>
    <time_frame>up to day 32</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with clinically significant changes in vital signs</measure>
    <time_frame>up to day 32</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with abnormal changes 12-lead ECG (electrocardiogram)</measure>
    <time_frame>up to day 32</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with abnormal changes in laboratory parameters</measure>
    <time_frame>up to day 32</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>up to 53 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of tolerability by investigator on a 4-point scale</measure>
    <time_frame>up to 480 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-24 (area under the concentration time curve of the analyte in plasma over the time interval from 0 to 24h after the first dose) - multiple dose groups</measure>
    <time_frame>up to 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax (maximum concentration of the analyte in plasma) - multiple dose groups</measure>
    <time_frame>up to 480 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Renal Insufficiency</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Linagliptin in subjects with normal renal function</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Linagliptin in patients with mild renal insufficiency (RI)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Linagliptin in patients with moderate RI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Linagliptin in patients with severe RI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Linagliptin in patients with end-stage renal disease (ESRD)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Linagliptin in patients with severe RI and Type 2 diabetes mellitus (T2DM)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Linagliptin in patients with normal renal function and T2DM</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Linagliptin - single dose</intervention_name>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_label>Group 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Linagliptin - Multiple dose</intervention_name>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 6</arm_group_label>
    <arm_group_label>Group 7</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female subjects with normal renal function, defined as a Creatinine Clearance&#xD;
             (CrCl) of &gt;80 mL/min on screening (Group 1) , or male or female patients with Type 2&#xD;
             diabetes mellitus (T2DM) and normal renal function, defined as a CrCl of &gt;80 mL/min on&#xD;
             screening (Group 7)&#xD;
&#xD;
          -  Male or female patients with Renal impairment (RI), determined by the value of CrCl on&#xD;
             Screening estimated according to the Cockcroft-Gault formula. Patients were classified&#xD;
             into groups by their CrCl values:&#xD;
&#xD;
               -  Mild RI: CrCl&gt;50 to ≤80 mL/min (Group 2)&#xD;
&#xD;
               -  Moderate RI: CrCl&gt;30 to ≤50 mL/min (Group 3)&#xD;
&#xD;
               -  Severe RI: CrCl≤30 mL/min (Group 4)&#xD;
&#xD;
               -  End-stage renal disease (ESRD): CrCl≤30 mL/min, requiring hemodialysis (Group 5)&#xD;
&#xD;
               -  T2DM and severe RI: CrCl≤30 mL/min (Group 6)&#xD;
&#xD;
          -  Age 18 to 80 years&#xD;
&#xD;
          -  BMI 18 to 40 kg/m2, and minimum body mass of at least 45 kg for females&#xD;
&#xD;
          -  Signed and dated written informed consent prior to admission to the study in&#xD;
             accordance with Good Clinical Practice (GCP) and the local legislation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Participants (with or without RI) who met any of the following criteria were not included&#xD;
        in this trial:&#xD;
&#xD;
          -  Relevant gastrointestinal tract surgery (except appendectomy, cholecystectomy, or&#xD;
             herniotomy)&#xD;
&#xD;
          -  Diseases of the central nervous system, such as epilepsy, seizures, relevant&#xD;
             neurological disorders, or psychiatric disorders&#xD;
&#xD;
          -  History of relevant orthostatic hypotension, fainting spells or blackouts; systolic&#xD;
             blood pressure &lt;100 or &gt;160 mm Hg, diastolic blood pressure &lt;60 or &gt;100 mm Hg, pulse&#xD;
             rate &lt;50 or &gt;100 1/min&#xD;
&#xD;
          -  Chronic or relevant acute infections&#xD;
&#xD;
          -  History of allergy/hypersensitivity (including drug allergies) that were deemed&#xD;
             relevant to the trial as judged by the investigator&#xD;
&#xD;
          -  Intake of drugs with a long half-life (&gt;24 h) within at least one month prior to study&#xD;
             start, or planned intake of study medication within ≤10 half-lives of administration&#xD;
             of another medication. Medications that patients with RI were currently taking for&#xD;
             treatment of renal disease were not included under this criterium.&#xD;
&#xD;
          -  Use of medications during the trial or within 10 days prior to administration of study&#xD;
             medication that might reasonably influence the results of the trial, based on&#xD;
             knowledge at the time of protocol preparation. Co-medications known to inhibit or&#xD;
             induce P-glycoprotein or CYP3A were not allowed. Inhibitors of P-glycoprotein or CYP3A&#xD;
             include protease inhibitors (such as ritonavir, lopinavir, nelfinavir); azole&#xD;
             antimycotics, (itraconazole, ketoconazole, miconazole); macrolide antibiotics,&#xD;
             (clarithromycin, erythromycin); amiodarone, cimetidine, diltiazem, fluvoxamine,&#xD;
             mibefradil, nefazodone, verapamil, tacrolimus, quinidine, reserpine, and cyclosporine&#xD;
             A. Inducers of P-gp or CYP3A include carbamazepine, phenobarbital, phenytoin,&#xD;
             rifabutin, rifampin, St. John's Wort and troglitazone. In uncertain cases, a&#xD;
             case-by-case decision was made after consultation with the sponsor.&#xD;
&#xD;
          -  Participation in a previous trial with an investigational drug within 2 months of&#xD;
             study start if the previous trial was a multiple dose study, or within 1 month of&#xD;
             study start if the previous trial was a single dose study&#xD;
&#xD;
          -  Smoker (more than 10 cigarettes or 3 cigars or 3 pipes per day)&#xD;
&#xD;
          -  Inability to refrain from smoking when confined to the study site on trial days&#xD;
&#xD;
          -  Alcohol abuse (more than 60 g/day in males or more than 40 g/day in females)&#xD;
&#xD;
          -  Drug abuse, in the investigator's judgment, based on review of the participant's&#xD;
             history and urine screening for abused substances&#xD;
&#xD;
          -  Veins unsuited for intravenous puncture on either arm (e.g. veins which were difficult&#xD;
             to locate, access or puncture, veins with a tendency to rupture during or after&#xD;
             puncture)&#xD;
&#xD;
          -  Blood donation (more than 100 mL within 4 weeks prior to administration of study&#xD;
             medication or during the trial)&#xD;
&#xD;
          -  Excessive physical activities (within 48 h prior to start of the trial or during the&#xD;
             trial)&#xD;
&#xD;
          -  Any laboratory value outside the reference range that was of clinical relevance&#xD;
             (exceptions were in patients with RI who had abnormal renal function tests or&#xD;
             deviations of clinical laboratory values that were related to renal impairment)&#xD;
&#xD;
          -  Inability to comply with the dietary regimen of study centre&#xD;
&#xD;
          -  Inability to understand and comply with protocol requirements, instructions and&#xD;
             protocol-stated restrictions&#xD;
&#xD;
        For female patients&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Positive pregnancy test (human chorionic gonadotropin (β HCG) in urine))&#xD;
&#xD;
          -  No adequate contraception in women of childbearing potential (adequate contraception&#xD;
             was considered to be sterilisation, use of an intrauterine device, or use of oral&#xD;
             contraception along with a barrier method)&#xD;
&#xD;
          -  Lactation period&#xD;
&#xD;
        Subjects with normal renal function (Group 1) and subjects with T2DM and normal renal&#xD;
        function (Group 7) who met the following criterium were not included in this trial:&#xD;
&#xD;
          -  Significant gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,&#xD;
             immunological or hormonal disorders as judged by the investigator&#xD;
&#xD;
        Patients with RI who met any of the following criteria were not included in this trial:&#xD;
&#xD;
          -  Moderate and severe concurrent liver function impairment (for example, due to&#xD;
             hepatorenal syndrome)&#xD;
&#xD;
          -  Patients with significant diseases other than renal impairment were excluded. A&#xD;
             significant disease was defined as a disease which in the opinion of the investigator&#xD;
             put the patient at risk during participation in the study, could influence the results&#xD;
             of the study, could influence the patient's ability to participate in the study, or&#xD;
             was an unstable condition. Patients with diabetes (for Groups 1 to 5) or hypertension&#xD;
             could be included in the trial if the disease was not significant according to these&#xD;
             criteria.&#xD;
&#xD;
          -  Haemoglobin &lt;8 g/dL, indicating severe anaemia of renal origin (use of erythropoietin&#xD;
             was allowed to maintain haematocrit)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/1218/1218.26_U10-1467-02.pdf</url>
    <description>Related Info</description>
  </link>
  <verification_date>June 2014</verification_date>
  <study_first_submitted>July 15, 2014</study_first_submitted>
  <study_first_submitted_qc>July 15, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2014</study_first_posted>
  <last_update_submitted>July 15, 2014</last_update_submitted>
  <last_update_submitted_qc>July 15, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 16, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Linagliptin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT02191228
org study id: 1218.26
nct id: NCT02191228
lead sponsor: 
The main objective of this study was to assess the effect of normal and impaired renal
      function on the safety, pharmacokinetics, and pharmacodynamics of linagliptin following oral
      administration of 5 mg daily for 7 days (Groups 1 to 3), 5 mg daily for 10 days (Groups 6 and
      7), or as a single dose (Groups 4 and 5)
allocation: Non-Randomized
intervention model: Parallel Assignment
primary purpose: Treatment
masking: None (Open Label)
measure: AUCτ,ss (area under the concentration time curve of the analyte in plasma over the time interval from 0 to 24h after the last dose at steady state) - multiple dose groups
time frame: up to 480 hours
measure: Cmax,ss (maximum concentration of the analyte in plasma at steady state) - multiple dose groups
time frame: up to 480 hours
measure: AUC0-24 (area under the concentration time curve of the analyte in plasma over the time interval from 0 to 24h after the first dose) - single dose groups
time frame: up to 24 hours
measure: Cmax (maximum concentration of the analyte in plasma) - single dose groups
time frame: up to 264 hours
measure: tmax,(ss) (time from last dosing to maximum concentration of the analyte in plasma after the first dose or at steady state) - multiple dose groups
time frame: up to 480 hours
measure: C24,(ss) (concentration of the analyte in plasma at steady state after administration of the first or last dose at the end of the dosing interval) - multiple dose groups
time frame: up to 480 hours
measure: λz,(ss) (terminal rate constant in plasma after single dose/at steady state) - multiple dose groups
time frame: up to 480 hours
measure: t1/2,(ss) (terminal half-life of the analyte in plasma after single dose/at steady state) - multiple dose groups
time frame: up to 480 hours
measure: MRTpo,(ss) (mean residence time of the analyte in the body after single dose/at steady state after oral administration) - multiple dose groups
time frame: up to 480 hours
measure: CL/F,(ss) (apparent clearance of the analyte in the plasma after extravascular administration after single dose/at steady state) - multiple dose groups
time frame: up to 480 hours
measure: Vz/F,(ss) (apparent volume of distribution during the terminal phase λz after single dose/at steady state following extravascular administration) - multiple dose groups
time frame: up to 480 hours
measure: AUC0-∞ (area under the concentration time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity after single dose in severely impaired or end stage renal disease (ESRD) patients)
time frame: up to 264 hours
measure: AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the time of the last quantifiable data point after single dose in severely impaired or ESRD patients)
time frame: up to 264 hours
measure: %AUCtz-∞ (percentage of area under the concentration-time curve of the analyte in plasma over the time interval from the time of the last quantifiable data point extrapolated to infinity after single dose in severely impaired or ESRD patients)
time frame: up to 264 hours
measure: Assessment of Plasma protein binding
time frame: predose Day 1
measure: Model-derived AUCτ,ss in severely impaired or ESRD patients
time frame: up to 264 hours
measure: Model-derived Cmax,ss in severely impaired or ESRD patients
time frame: up to 264 hours
measure: Change in Dipeptidyl peptidase IV (DPP-4) activity in plasma
time frame: up to 480 hours
measure: Number of patients with abnormal findings in physical examination
time frame: up to day 32
measure: Number of patients with clinically significant changes in vital signs
time frame: up to day 32
measure: Number of patients with abnormal changes 12-lead ECG (electrocardiogram)
time frame: up to day 32
measure: Number of patients with abnormal changes in laboratory parameters
time frame: up to day 32
measure: Number of patients with adverse events
time frame: up to 53 days
measure: Assessment of tolerability by investigator on a 4-point scale
time frame: up to 480 hours
measure: AUC0-24 (area under the concentration time curve of the analyte in plasma over the time interval from 0 to 24h after the first dose) - multiple dose groups
time frame: up to 24 hours
measure: Cmax (maximum concentration of the analyte in plasma) - multiple dose groups
time frame: up to 480 hours
arm group label: Group 1
arm group type: Experimental
description: Linagliptin in subjects with normal renal function
arm group label: Group 2
arm group type: Experimental
description: Linagliptin in patients with mild renal insufficiency (RI)
arm group label: Group 3
arm group type: Experimental
description: Linagliptin in patients with moderate RI
arm group label: Group 4
arm group type: Experimental
description: Linagliptin in patients with severe RI
arm group label: Group 5
arm group type: Experimental
description: Linagliptin in patients with end-stage renal disease (ESRD)
arm group label: Group 6
arm group type: Experimental
description: Linagliptin in patients with severe RI and Type 2 diabetes mellitus (T2DM)
arm group label: Group 7
arm group type: Experimental
description: Linagliptin in patients with normal renal function and T2DM
intervention type: Drug
intervention name: Linagliptin - single dose
arm group label: Group 4
arm group label: Group 5
intervention type: Drug
intervention name: Linagliptin - Multiple dose
arm group label: Group 1
arm group label: Group 2
arm group label: Group 3
arm group label: Group 6
arm group label: Group 7
criteria: 
gender: All
minimum age: 18 Years
maximum age: 80 Years
healthy volunteers: Accepts Healthy Volunteers
url: http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/1218/1218.26_U10-1467-02.pdf
description: Related Info
responsible party type: Sponsor
mesh term: Renal Insufficiency
mesh term: Linagliptin